Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, November 2, 2021, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8178994. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, Hong Kong, Switzerland, Taiwan, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005382/en/

Deciphera Pharmaceuticals Aktie

23,00 €
-0,86 %
Ein leichter Kursrückgang bei Deciphera Pharmaceuticals heute, um -0,86 %.
Eine klare Neigung zu Buy-Einschätzungen bei Deciphera Pharmaceuticals, ohne Sell-Einschätzungen.
Das niedrigere Kursziel von 21 € im Vergleich zum aktuellen Kurs von 23.0 € für Deciphera Pharmaceuticals führt zu einem negativen Potenzial von -8.7%.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare